A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

NCT05975060 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: XBB.1.5 Vaccine (Booster)
BIOLOGICAL: XBB.1.5 Vaccine (single dose)

Sponsor

Novavax